CVSA Covista Inc.
FY2025 10-K
Covista Inc. (CVSA) filed its fiscal year 2025 10-K annual report with the SEC on Aug 7, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Provider of postsecondary education with focus on medical and healthcare programs
- • Emphasis on regulatory compliance risks impacting Title IV funding and clinical placement limitations for medical schools
Management Discussion & Analysis
- • No revenue or profit figures disclosed in the MD&A section
- • Key risk: potential fines, debt discharge liabilities, or suspension from Title IV programs due to "substantial misrepresentation" claims
Risk Factors
- • Regulatory risk from U.S. Department of Education (ED) Borrower Defense to Repayment rules affecting Title IV loan obligations recovery
- • Geopolitical exposure to U.S. federal and state investigations, risking Title IV program eligibility restrictions across multiple institutions
Financial SummaryXBRL
Revenue
$1.8B
Net Income
$237M
Operating Margin
19.1%
Net Margin
13.3%
ROE
16.5%
Total Assets
$2.8B
EPS (Diluted)
$6.18
Operating Cash Flow
$338M
Source: XBRL data from Covista Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Covista Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.